Marisa Wexler, MS,  senior science writer—

The eighth annual BreatheCon, a virtual event hosted by the Cystic Fibrosis Foundation that brings together adults with cystic fibrosis (CF), is coming up Feb. 9-10. BreatheCon 2024 will focus on the individual experience of the CF journey. Participants will have opportunities to share their own stories,…

Results of three global clinical trials of a new triple-combination CFTR modulator therapy for cystic fibrosis (CF) —  vanzacaftor, tezacaftor and deutivacaftor — are expected shortly, Vertex Pharmaceuticals, the therapy’s developer, announced. Two of these Phase 3 trials, SKYLINE 103 (NCT05076149) and SKYLINE 102 (NCT05033080), which tested the…

Treatment with the inhaled antibiotic aztreonam can stabilize lung function in people with cystic fibrosis (CF) who have chronic infections of the bacterium Pseudomonas aeruginosa. That’s according to “Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in patients with cystic fibrosis: real-life effectiveness,”…

People with cystic fibrosis (CF) who have chronic inflammation in the nose are less likely to need sinus surgery if they are taking the triple-combination CFTR modulator treatment Kaftrio (elexacaftor/tezacaftor/ivacaftor). That’s according to “Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery…

Inflammatory molecules that serve as markers of infection or other problems can be measured in the nasal fluid of babies with cystic fibrosis (CF), collected using filter paper placed in a nostril. Changes in the levels of some of these molecules, using this noninvasive method, were seen in infants…

A newborn screening program in New Jersey failed to identify cystic fibrosis (CF) in five children, all of whom went on to have severe lung disease, a new study reports. Based on the findings, New Jersey’s newborn screening program has been updated to include screening for many more disease-causing…

Researchers hope a new tool that can provide disease-specific education and resources about a lung transplant for people with cystic fibrosis (CF) will be able to make inroads among patients who’ve historically had poor access to the procedure. The development of the tool, called Take on Transplant, was introduced…

Treatment with the inhaled gene therapy 4D-710 led to clinically meaningful quality of life gains for people with cystic fibrosis (CF) in a clinical trial, according to data announced by 4D Molecular Therapeutics (4DMT), the therapy’s developer. Treatment also led to high expression of the CFTR protein…

The first person with cystic fibrosis (CF) has been dosed with CM001, an experimental inhaled therapy being developed by Cystetic Medicines to treat all people with CF, including those who aren’t eligible for modulators. “Dosing the first person with CF represents a critical milestone in our mission to…

Moligo Technologies is teaming up with Nationwide Children’s Hospital on a new project to develop a non-viral gene therapy approach for treating cystic fibrosis (CF) and other diseases that affect the lungs. Instead of using a modified virus to deliver a gene therapy into a patient’s body, the…